Paclitaxel coated balloon in the treatment of femoral popliteal artery disease
10.3760/cma.j.cn113855-20210120-00042
- VernacularTitle:紫杉醇药物球囊治疗股腘动脉粥样硬化性病变的疗效分析
- Author:
Yongbao ZHANG
1
;
Lequn TENG
;
Jie FANG
;
Xinnong LIU
;
Chengjia QU
;
Chenyang SHEN
Author Information
1. 中国医学科学院阜外医院血管中心，北京 100037
- Keywords:
Arteriosclerosis;
Angioplasty;
Drug-coated balloon;
Femoropopliteal artery
- From:
Chinese Journal of General Surgery
2022;37(3):184-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the clinical efficiency of paclitaxel drug coated balloon (DCB) in femoral popliteal artery disease.Methods:Retrospective analysis was made on 125 patients (141 limbs) admitted from Jun 2016 to Jul 2019 for femoral popliteal disease treated with DCB.Results:Median follow-up time was 19 months. The average lesion length was (138±78) mm, with an overall cumulative primary patency rate of 81.4% and 60.8% at 12 and 24 months postoperatively and f-TLR rates of 90.1% and 83.0%, respectively. In a total of 109 primary lesions, subgroup analysis showed that among the TASC C/D primary lesions, the primary patency rate was significantly lower in those with combined severe calcification and the f-TLR rate in those with popliteal involved lesions. TASC grade C/D lesions, severe calcified lesions were independent risk factors for patency, while hypertension was an independent protective factor.In-stent restenosis (ISR) target lesions involving the popliteal segment had a significantly worse prognosis than ISR of the superficial femoral artery.Conclusion:DCB in the treatment of lower femoral popliteal artery lesions can achieve a satisfactory medium-term patency outcome, while the efficacy for complex lesions still needs further improvement.
